This study is a multicenter, open-label, Phase II, single-arm clinical trial, with a planned enrollment of 200 to 300 subjects. Its primary objective is to evaluate the safety and efficacy of TQH2722 injection in the treatment of seasonal allergic rhinitis.
Aged 18-75, with no gender restrictions.
Diagnosed with seasonal allergic rhinitis.
Positive allergen test result.
The subjects have sufficient exposure to pollen during the pollen season.
Any abnormal laboratory test value during the screening period or randomization.
Any disease that researchers consider to be unstable and may affect the patient's safety throughout the entire study period, or affect the study results or their interpretation, or hinder the patient's ability to complete the entire study process.
Patients with active autoimmune diseases.
Known or suspected immunosuppressants.